News

Lysogene, a pioneering Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast…
Read More...

TwinStrand Biosciences announced the launch of TwinStrand Duplex Sequencing Technology kits at the annual Advances in Genome Biology and Technology (AGBT) General Meeting in Marco…
Read More...

EmCyte announces its FDA 510(k) clearance for its PurePRP Supraphysiologic Concentrating System for platelet rich plasma. The system's 510(k) number is BK190317 and is cleared to be…
Read More...

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting…
Read More...

Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to…
Read More...

Vir Biotechnology, Inc. and WuXi Biologics announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of…
Read More...

Bicycle Therapeutics plc announced that it has entered into a strategic collaboration agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize novel…
Read More...

Pandion Therapeutics, Inc., a biotechnology company developing modular protein therapeutics for autoimmune disease, announced the dosing of the first subject in a Phase 1 clinical trial…
Read More...

Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA)…
Read More...

Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential…
Read More...

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients…
Read More...

STADA AG is significantly expanding its global OTC business agreeing to acquire a portfolio of well-established local and regional consumer healthcare brands from GlaxoSmithKline (GSK)…
Read More...

Harbour BioMed (HBM) announced completion of a Phase 1 study of HBM9161, a fully human anti-FcRn monoclonal antibody, to evaluate its safety, tolerability, pharmacokinetics and…
Read More...

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced it has entered…
Read More...

Vifor Pharma announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the second largest…
Read More...

Roche announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq…
Read More...

LumaCyte, an advanced bioanalytical instrumentation company specializing in vaccine and cell and gene therapy bioprocess, production, and R&D analytical capabilities, announces its…
Read More...

Hummingbird Bioscience, an innovative biotherapeutics company pioneering the discovery of new breakthrough antibody therapeutics for difficult-to-treat conditions, announced it has…
Read More...

FORMA Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, announced the U.S. Food and Drug Administration (FDA) has granted…
Read More...

Humanetics Corporation (Humanetics) announced that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM’s assets…
Read More...